Neurotype Inc. Secures $1M Grant to Revolutionize Addiction Treatment with FDA-Regulated Neurofeedback Technology

We are thrilled to announce that Neurotype Inc. has successfully raised $1,000,000 in its latest round of funding—a milestone that reinforces our commitment to revolutionizing addiction treatment through innovative technology. Neurotype Inc. is at the forefront of developing cutting-edge brain sensors and digital therapeutics designed to improve the treatment of cravings in both drug and food addictions. The recent capital infusion will accelerate our research and development efforts, particularly as we progress toward finalizing an FDA-regulated device that leverages advanced neurofeedback technology. This pioneering device is engineered to offer personalized prevention strategies for drug cravings and to reduce the risk of relapse, especially in individuals battling Opioid Use Disorder. The funding will be instrumental in scaling up clinical trials and further refining our technology to ensure it meets the highest standards of safety and efficacy. By harnessing real-time neural data, our innovative approach aims to empower healthcare professionals with actionable insights and provide patients with customized therapeutic interventions that address the root causes of their cravings. Our vision is to create a paradigm shift in addiction treatment—one that moves away from one-size-fits-all solutions towards targeted, patient-specific care. This investment not only validates the disruptive potential of our solutions but also paves the way for future advancements in the field of neurotechnology and addiction medicine. We extend our deepest gratitude to our investors, partners, and the broader community for their unwavering support as we continue our mission to enhance lives through science and technology. With this funding, Neurotype Inc. is more determined than ever to transform the landscape of addiction treatment and offer hope to millions affected by these challenging conditions.